Glenmark Stock - analyst consensus and outlook midyear
17.06.2026 - 21:49:10 | ad-hoc-news.de
Edited by ad hoc news Analyst & Consensus Desk. Verified prior to publication on 06/17/2026, 21:48 CET. Details in the imprint.
Glenmark (INE935A01035) remains a closely watched Indian mid-cap in pharmaceuticals as investors reassess consensus expectations after its recent quarterly earnings and ongoing balance-sheet cleanup. Analysts continue to monitor margin trends, debt reduction and the evolving specialty and generics mix.
Background and price data on Glenmark stock
All current news, regulatory filings and market data on Glenmark stock can be found in the dedicated topic hub on ad-hoc-news.de and on the company’s Investor Relations page.
What recent numbers show
Glenmark Pharmaceuticals Ltd. reported consolidated revenue of roughly INR 3,635 crore for its most recently reported quarter, with India and the US as the key contributors to sales. Management has emphasized cost discipline and selective R&D spending to support margins and debt reduction.
The company has also been reshaping its portfolio, including its past demerger of Glenmark Life Sciences and a focus on branded generics, complex generics and specialty products in respiratory and dermatology. This reshaping is meant to simplify the structure and strengthen the core branded generics franchise.
Analyst views and consensus
Sell-side coverage on Glenmark remains relatively limited compared with large-cap Indian peers, but available reports point to cautious optimism on profitability after the recent balance-sheet measures and portfolio steps. Analysts often highlight US pricing pressure and regulatory risks as ongoing constraints for valuation.
Consensus data compiled by market platforms suggests that expectations for earnings growth over the next one to two years remain moderate, reflecting both currency and competitive headwinds. Net-net, the stock is widely seen as a medium-risk name among Indian mid-cap pharma companies, sensitive to regulatory news and margin surprises.
How Glenmark makes money
Glenmark generates most of its revenue from branded generics, particularly in India and other emerging markets, alongside generics and specialty products in regulated markets such as the US and Europe. Its key therapeutic areas include respiratory, dermatology and oncology, supported by an active pipeline of complex generics and select biologics.
Where the stock trades today
The shares of Glenmark (INE935A01035) trade on the National Stock Exchange of India at INR 1,000.00 as of 06/17/2026, 21:30 IST.
Key facts on Glenmark stock
- Company: Glenmark Pharmaceuticals Ltd.
- ISIN: INE935A01035
- WKN: A0HM9T
- Ticker: GLENMARK
- Venue: NSE
- Price (as of 06/17/2026, 21:30 IST): 1,000.00 INR
- Market cap: 284,000,000,000 INR (as of 06/17/2026)
- Sector / Industry: Health Care / Pharmaceuticals
- Index membership: Nifty Midcap index family
- Next earnings date: not officially scheduled
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
